Literature DB >> 16186805

The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.

Y Xie1, K Xu, B Dai, Z Guo, T Jiang, H Chen, Y Qiu.   

Abstract

Protein kinase Pim-1 has been implicated in the development of hematopoietic and prostatic malignancies. Here, we present the evidence that two isoforms, the 44 and 33 kDa Pim-1, are expressed in all human prostate cancer cell lines examined. The subcellular localization of human 44 kDa Pim-1 is primarily on the plasma membrane, while the 33 kDa isoform is present in both the cytosol and nucleus in PCA cells. The 44 kDa Pim-1 contains the proline-rich motif at the N-terminus and directly binds to the SH3 domain of tyrosine kinase Etk. Such interaction leads to the activation of Etk kinase activity possibly by competing with the tumor suppressor p53. This is corroborated by the fact that overexpression of the 44 kDa Pim-1 in prostate cancer cells confers the resistance to chemotherapeutic drugs. Our results suggest that these two isoforms of Pim-1 kinase may regulate distinct substrates and the 44 kDa Pim-1 may play a more prominent role in drug resistance in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16186805     DOI: 10.1038/sj.onc.1209058

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  52 in total

Review 1.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

Review 2.  Nonreceptor tyrosine kinases in prostate cancer.

Authors:  Yu-Ming Chang; Hsing-Jien Kung; Christopher P Evans
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

3.  Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.

Authors:  Andrea L Casillas; Rachel K Toth; Alva G Sainz; Neha Singh; Ankit A Desai; Andrew S Kraft; Noel A Warfel
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

4.  Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.

Authors:  Jui-Ling Hsu; Pui-Kei Leong; Yunn-Fang Ho; Lih-Ching Hsu; Pin-Hsuan Lu; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

5.  Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.

Authors:  Jin H Song; Neha Singh; Libia A Luevano; Sathish K R Padi; Koichi Okumura; Virginie Olive; Stephen M Black; Noel A Warfel; David W Goodrich; Andrew S Kraft
Journal:  Mol Cancer Ther       Date:  2018-09-06       Impact factor: 6.261

6.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

7.  RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

Authors:  Riet van der Meer; Ha Yong Song; Seong-Hoon Park; Sarki A Abdulkadir; Meejeon Roh
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

8.  PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis.

Authors:  Xiu Feng Hu; Jie Li; Scott Vandervalk; Zeping Wang; Nancy S Magnuson; Pei Xiang Xing
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

9.  Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.

Authors:  Sen Chen; Xinnong Jiang; Christina A Gewinner; John M Asara; Nicholas I Simon; Changmeng Cai; Lewis C Cantley; Steven P Balk
Journal:  Sci Signal       Date:  2013-05-28       Impact factor: 8.192

10.  PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.

Authors:  J J Gu; Z Wang; R Reeves; N S Magnuson
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.